RAPT Therapeutics director granted 4,956 RSUs

RAPT Therapeutics director Lori Lyons-Williams reported an annual equity award in the form of restricted stock units.

Rhea-AI Filing Summary

RAPT Therapeutics director Lori Lyons-Williams reported an annual equity award in the form of restricted stock units. On January 30, 2026, she was granted 4,956 RSUs of RAPT Therapeutics common stock at a price of $0 per unit under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs will fully vest on the first anniversary of the grant date, with each RSU converting into one share of common stock upon vesting. Following this grant, she beneficially owns 4,956 common shares, held directly.

Insider Trade Summary

Grant/Award: 4,956 shares

Grant/Award 1 txn

Insider Lyons-Williams Lori

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,956	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,956 shares (Direct)

Footnotes (1)

1. F1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RAPT (RAPT) director Lori Lyons-Williams report in this Form 4 filing?

Lori Lyons-Williams reported receiving 4,956 restricted stock units from RAPT Therapeutics as an annual director equity award. The grant is recorded as common stock acquired at $0 per share and is held directly following the reported transaction.

How many RAPT Therapeutics RSUs were granted to Lori Lyons-Williams?

She was granted 4,956 restricted stock units of RAPT Therapeutics common stock. These units come from the company’s non-employee director compensation policy and represent a contingent right to receive an equal number of common shares once the vesting conditions are satisfied.

When do Lori Lyons-Williams’ RAPT (RAPT) restricted stock units vest?

The 4,956 restricted stock units fully vest on the first anniversary of the January 30, 2026 grant date. Once vested, each RSU converts into one share of RAPT Therapeutics common stock, delivering actual share ownership instead of a contingent right.

What is the acquisition price of the RSUs granted to the RAPT director?

The Form 4 shows the 4,956 common stock units were acquired at a price of $0 per share. This reflects an equity compensation grant under the non-employee director policy rather than an open-market purchase funded with the director’s own cash.

How many RAPT shares does Lori Lyons-Williams beneficially own after this transaction?

After the reported grant, Lori Lyons-Williams beneficially owns 4,956 shares of RAPT Therapeutics common stock. The filing indicates these shares are held directly, aligning with the restricted stock unit award that converts into common shares upon vesting.

What policy governs the RSU grant to the RAPT Therapeutics director?

The grant was made under RAPT Therapeutics’ Amended & Restated Non-Employee Director Compensation Policy. This policy provides annual restricted stock unit awards to non-employee directors, which in this case vest in full one year after the January 30, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyons-Williams Lori

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/30/2026		A		4,956	A	$0	4,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

	/s/ Rodney Young, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.